Year,SDG Series,Reference area,Value
2007,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,94.1
2008,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,95.3
2009,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,95.4
2010,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,96.5
2011,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,95.1
2012,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,96.2
2013,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,96.9
2014,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,95.8
2015,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,96.6
2016,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,96.1
2017,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,93.4
2018,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,94.5
2019,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,94.351083
2020,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,88.157251
2021,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),,88.796593
2007,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,93.4
2008,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,96.8
2009,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,95.4
2010,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,96.8
2011,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,96.7
2012,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,98.3
2013,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,97.7
2014,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,98.9
2015,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,98.6
2016,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,98.1
2017,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,96.7
2018,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,96.6
2019,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,98.322619
2020,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,91.684706
2021,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Batken,86.908583
2007,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,93.6
2008,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,95.6
2009,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,95.9
2010,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,95.9
2011,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,94.2
2012,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,95.9
2013,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,97.8
2014,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,94.8
2015,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,96.1
2016,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,95.8
2017,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,93.8
2018,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,96.1
2019,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,90.174029
2020,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,87.415504
2021,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Jalal-Abad,89.680107
2007,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,93.9
2008,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,95.2
2009,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,95.3
2010,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,97.2
2011,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,93.6
2012,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,96.9
2013,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,97.3
2014,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,91.3
2015,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,98.0
2016,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,95.9
2017,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,96.1
2018,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,95.0
2019,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,94.575714
2020,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,87.604354
2021,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Issyk-Kul,95.77591
2007,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,94.4
2008,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,95.2
2009,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,95.3
2010,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,96.8
2011,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,95.5
2012,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,97.4
2013,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,98.0
2014,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,97.6
2015,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,97.2
2016,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,96.8
2017,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,97.0
2018,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,94.8
2019,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,97.59292
2020,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,90.958705
2021,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Naryn,96.517042
2007,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,94.4
2008,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,94.5
2009,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,95.1
2010,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,95.5
2011,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,93.6
2012,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,93.0
2013,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,96.2
2014,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,98.3
2015,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,97.1
2016,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,98.5
2017,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,96.6
2018,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,95.8
2019,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,99.33564
2020,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,95.543628
2021,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh,90.31153
2007,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,94.0
2008,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,94.8
2009,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,94.6
2010,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,96.8
2011,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,95.3
2012,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,96.0
2013,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,96.2
2014,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,93.4
2015,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,96.8
2016,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,95.2
2017,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,93.1
2018,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,95.3
2019,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,92.698706
2020,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,94.171956
2021,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Talas,90.746325
2007,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,94.0
2008,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,95.5
2009,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,95.5
2010,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,96.3
2011,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,96.8
2012,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,97.6
2013,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,96.3
2014,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,96.0
2015,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,97.0
2016,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,97.5
2017,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,91.8
2018,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,92.5
2019,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,91.652622
2020,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,89.92219
2021,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Chui,90.894108
2007,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),95.0
2008,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),94.9
2009,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),95.5
2010,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),96.8
2011,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),96.4
2012,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),97.2
2013,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),96.6
2014,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),93.7
2015,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),94.0
2016,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),90.5
2017,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),86.5
2018,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),90.3
2019,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),92.018905
2020,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),73.377391
2021,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Bishkek (city),81.065681
2007,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),95.2
2008,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),96.7
2009,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),95.4
2010,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),95.7
2011,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),95.2
2012,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),98.5
2013,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),99.2
2014,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),96.0
2015,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),97.6
2016,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),96.7
2017,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),98.0
2018,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),95.2
2019,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),95.586032
2020,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),87.340379
2021,Proportion of the target population with access to 3 doses of diphtheria-tetanus-pertussis (DTP3),Osh (city),85.088889
2007,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,98.8
2008,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,99.1
2009,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,98.9
2010,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,98.3
2011,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,97.2
2012,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,97.7
2013,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,98.666102
2014,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,95.6
2015,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,99.1
2016,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,97.0
2017,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,94.7
2018,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,96.244215
2019,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,97.245414
2020,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,93.789319
2021,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),,93.378399
2007,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,99.2
2008,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,99.0
2009,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,99.9
2010,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,97.2
2011,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,95.7
2012,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,100.0
2013,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,99.9
2014,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,98.9
2015,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,97.6
2016,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,99.9
2017,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,98.7
2018,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,92.454654
2019,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,98.254513
2020,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,98.728939
2021,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Batken,93.091417
2007,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,97.8
2008,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,99.2
2009,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,98.3
2010,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,98.3
2011,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,100.0
2012,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,99.0
2013,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,99.6
2014,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,91.7
2015,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,100.0
2016,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,95.7
2017,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,88.8
2018,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,93.49863
2019,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,93.035179
2020,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,91.334273
2021,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Jalal-Abad,94.815062
2007,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,99.0
2008,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,99.7
2009,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,99.7
2010,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,99.2
2011,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,96.9
2012,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,95.7
2013,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,97.4
2014,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,95.6
2015,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,98.9
2016,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,97.7
2017,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,95.1
2018,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,96.51199
2019,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,97.67698
2020,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,96.09807
2021,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Issyk-Kul,100.537815
2007,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,99.4
2008,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,99.1
2009,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,98.9
2010,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,99.5
2011,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,96.7
2012,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,97.6
2013,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,97.3
2014,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,97.7
2015,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,98.1
2016,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,98.1
2017,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,97.0
2018,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,97.646444
2019,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,98.140747
2020,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,96.233184
2021,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Naryn,100.335258
2007,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,98.9
2008,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,99.5
2009,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,99.8
2010,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,99.7
2011,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,94.7
2012,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,96.6
2013,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,97.9
2014,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,96.1
2015,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,99.0
2016,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,99.2
2017,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,96.8
2018,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,98.10916
2019,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,99.619945
2020,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,97.454999
2021,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh,93.789893
2007,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,98.6
2008,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,99.2
2009,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,97.6
2010,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,97.1
2011,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,97.7
2012,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,98.8
2013,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,97.7
2014,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,94.3
2015,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,97.1
2016,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,97.0
2017,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,95.6
2018,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,98.413291
2019,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,95.974889
2020,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,95.177033
2021,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Talas,95.401432
2007,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,99.1
2008,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,97.4
2009,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,98.7
2010,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,96.4
2011,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,97.1
2012,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,96.4
2013,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,99.3
2014,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,96.5
2015,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,98.6
2016,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,95.0
2017,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,96.3
2018,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,97.43813
2019,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,99.450649
2020,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,97.514722
2021,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Chui,92.308749
2007,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),99.8
2008,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),99.9
2009,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),98.6
2010,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),99.0
2011,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),97.4
2012,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),97.7
2013,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),98.4
2014,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),95.6
2015,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),99.8
2016,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),95.1
2017,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),91.7
2018,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),96.281062
2019,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),96.444387
2020,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),83.697508
2021,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Bishkek (city),89.338843
2007,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),98.8
2008,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),98.9
2009,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),98.2
2010,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),97.4
2011,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),99.7
2012,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),98.1
2013,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),98.7
2014,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),99.9
2015,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),99.7
2016,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),96.8
2017,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),97.7
2018,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),99.425085
2019,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),97.981883
2020,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),93.662127
2021,Proportion of the target population with access to measles-containing-vaccine second-dose (MCV2),Osh (city),87.955556
2015,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),,96.8
2016,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),,97.2
2017,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),,94.2
2018,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),,92.0
2019,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),,95.083643
2020,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),,88.782542
2021,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),,89.631204
2015,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Batken,97.3
2016,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Batken,99.3
2017,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Batken,96.3
2018,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Batken,94.6
2019,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Batken,99.597512
2020,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Batken,83.440107
2021,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Batken,89.204466
2015,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Jalal-Abad,97.3
2016,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Jalal-Abad,95.9
2017,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Jalal-Abad,94.5
2018,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Jalal-Abad,93.8
2019,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Jalal-Abad,90.089857
2020,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Jalal-Abad,88.195819
2021,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Jalal-Abad,84.751749
2015,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Issyk-Kul,98.2
2016,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Issyk-Kul,96.4
2017,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Issyk-Kul,96.3
2018,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Issyk-Kul,95.0
2019,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Issyk-Kul,94.992818
2020,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Issyk-Kul,88.268865
2021,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Issyk-Kul,96.201681
2015,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Naryn,96.8
2016,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Naryn,96.7
2017,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Naryn,97.0
2018,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Naryn,95.1
2019,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Naryn,97.283381
2020,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Naryn,91.250904
2021,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Naryn,95.567145
2015,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh,96.3
2016,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh,98.8
2017,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh,97.2
2018,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh,92.1
2019,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh,98.41451
2020,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh,95.711275
2021,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh,91.330444
2015,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Talas,97.2
2016,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Talas,96.1
2017,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Talas,94.0
2018,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Talas,96.0
2019,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Talas,94.297841
2020,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Talas,95.762224
2021,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Talas,91.368262
2015,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Chui,97.6
2016,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Chui,98.7
2017,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Chui,92.6
2018,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Chui,92.1
2019,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Chui,94.916128
2020,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Chui,90.955903
2021,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Chui,92.345374
2015,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Bishkek (city),95.0
2016,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Bishkek (city),94.8
2017,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Bishkek (city),90.4
2018,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Bishkek (city),83.4
2019,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Bishkek (city),93.823491
2020,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Bishkek (city),79.378126
2021,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Bishkek (city),88.660287
2015,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh (city),97.9
2016,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh (city),96.8
2017,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh (city),90.0
2018,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh (city),93.9
2019,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh (city),95.896254
2020,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh (city),87.352779
2021,Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3),Osh (city),84.944444
